MCRB250117C2000
- 0.05
- 0.000.00%
Seres Therapeutics Newsroom
The Past Three Years for Seres Therapeutics (NASDAQ:MCRB) Investors Has Not Been Profitable
Seres Therapeutics to Present at J.P. Morgan Healthcare Conference, Highlighting SER-155 Breakthrough Therapy Designation
Optimistic Buy Rating for Seres Therapeutics: Breakthrough Therapy Designation and Financial Stability Boost Confidence
Seres Therapeutics' SER-155 Receives FDA Breakthrough Therapy Designation for Bloodstream Infection Reduction
Express News | Seres Therapeutics Inc - FDA Meeting on Next Study of Ser-155 Expected in Q1 2025
Express News | FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ Ser-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (Allo-Hsct)
FDA Grants Breakthrough Therapy Designation to Seres Therapeutics' SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT)
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference
Benign Growth For Seres Therapeutics, Inc. (NASDAQ:MCRB) Underpins Stock's 30% Plummet
Seres Therapeutics Is Maintained at Buy by Canaccord Genuity
Seres Therapeutics Price Target Maintained With a $10.00/Share by Canaccord Genuity
Promising Developments and Financial Stability Drive Buy Rating for Seres Therapeutics
Seres Therapeutics Reports Q3 2024 Results and Strategic Progress
Express News | Chardan Capital Maintains Buy on Seres Therapeutics, Maintains $1.25 Price Target
TD Cowen Maintains Seres Therapeutics(MCRB.US) With Buy Rating
Seres Therapeutics (MCRB) Gets a Buy From TD Cowen
Seres Therapeutics, Inc. (MCRB) Q3 2024 Earnings Call Transcript Summary
Seres Therapeutics | 10-Q: Q3 2024 Earnings Report
Seres Therapeutics, Inc. (MCRB) Q3 2024 Earnings Call Transcript
Seres Therapeutics Faces Nasdaq Challenge Amid Trial Success